Amilorid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amilorid

Property Description
Active Ingredients Amiloride hydrochloride, Hydrochlorothiazide
Form Tablet (Oral Preparation)
Pharmacological Class Diuretic (Potassium-Sparing and Thiazide Combination)
General Purpose Management of excess body fluid and hypertension
Origin Synthetic Pharmaceutical Combination

Amiloride and Hydrochlorothiazide: What Type of Medicine Is It?

This medicine is a synthetic, fixed-dose combination product primarily classified as a diuretic, serving the functional role of an antihypertensive agent. It is supplied as an oral preparation (tablet) and contains two distinct active ingredients: Amiloride hydrochloride and Hydrochlorothiazide. The use of this particular pharmaceutical combination is widely recognized for providing effective fluid management in patients prone to electrolyte disruptions.

The two primary components define its type: Hydrochlorothiazide is a thiazide diuretic, and Amiloride is a potassium-sparing diuretic. This combination is commonly marketed under various commercial names, reflecting its status as a widely used, essential component in long-term pharmacotherapy. The oral route of administration makes the product a convenient choice for target patient groups, predominantly adults.


What is the General Purpose of Combining Amiloride and Hydrochlorothiazide?

The general purpose of this combination is to promote the elimination of excessive water and salt from the body, which aids in managing fluid retention and stabilizing blood pressure. This physiological action leads to a powerful natriuretic effect and increased diuresis. The utility of combination diuretics is recognized in achieving desired therapeutic outcomes.

The differentiating factor of this specific fixed-dose pairing is the Amiloride component's critical secondary role in promoting potassium conservation, directly counteracting the potassium-depleting effect common to the thiazide diuretic component. This makes the drug a preferred option for patients who require effective volume reduction but must maintain stable electrolyte balance. The overall result is a balanced approach to volume management, contributing significantly to its established role as an antihypertensive agent.

Regulatory References

  1. National Institutes of Health, MedlinePlus
  2. Food and Drug Administration (FDA)

What side effects are possible with Amilorid?

Possible Side Effects and Safety Information

This section describes the officially documented safety profile and possible adverse reactions for the Amiloride and Hydrochlorothiazide combination, as classified by government regulatory authorities.


Key System-Organ Classes and Common Regulatory Observations

Adverse reactions are formally grouped according to the body system affected. Common effects are often related to the Nervous System (e.g., headache, dizziness) and Gastrointestinal System (e.g., nausea, constipation, dry mouth). General systemic symptoms like fatigue and weakness are also frequently documented.

Less common or rare events are classified across other systems, including Cardiovascular (e.g., palpitation, arrhythmia) and Dermatologic (e.g., rash).


Serious Adverse Reactions and Safety Constraints

The primary safety concern documented in regulatory labeling is the risk of Hyperkalemia (excessive potassium in the blood), an effect associated with the Amiloride component that can lead to life-threatening cardiac effects. Conversely, the Hydrochlorothiazide component may still cause Hypokalemia and Hyponatremia.

Serious rare events include Jaundice, Pancreatitis, and certain blood dyscrasias (e.g., Aplastic Anemia). The medication is contraindicated in specific high-risk clinical situations, including pre-existing Hyperkalemia (potassium levels exceeding 5.5 mEq/L) and Anuria (absence of urine production).


Population-Specific and Time-Related Safety

Regulatory documents emphasize that the risk of Hyperkalemia is elevated in individuals with existing renal impairment. Caution is also advised for patients with severe hepatic impairment due to the potential for precipitating hepatic coma. Regarding exposure patterns, orthostatic hypotension (dizziness upon standing) is officially noted as being more likely to occur at the start of therapy.

Overdose and Emergency Response

Amiloride overdose is expected to primarily cause an exaggeration of its known therapeutic and adverse effects, chiefly involving disturbances in fluid and electrolyte balance. The most significant concern is hyperkalemia (abnormally high potassium levels in the blood), which can be life-threatening if uncorrected, especially in patients with kidney impairment, diabetes, or those taking other potassium-raising medications.

Symptoms of Overdose or Severe Toxicity

The most likely signs and symptoms of a significant overdose or severe toxicity are related to volume depletion (dehydration) and hyperkalemia. These may include:

  • Cardiovascular: Slow or irregular heartbeat (arrhythmia), faintness, and severe dizziness due to low blood pressure.
  • Neuromuscular: Unusual weakness, fatigue, numbness, or tingling sensations in the extremities (paresthesia), and muscle cramps.
  • Gastrointestinal: Nausea, vomiting, and diarrhea.

When to Seek Help

If you suspect an overdose, or if you experience any signs of severe hyperkalemia or dehydration, seek emergency medical attention immediately by contacting emergency services or a poison control center. Do not wait for symptoms to worsen.

Critical symptoms requiring urgent care include:

Symptom Category Critical Signs
Heart Very slow or irregular heartbeat, palpitations, chest pain
Mental State Severe dizziness, confusion, fainting
Respiration Difficulty breathing, shortness of breath

Management of Amiloride overdose is primarily supportive, focusing on correcting dehydration and, most importantly, treating hyperkalemia to prevent dangerous cardiac rhythm changes. Amiloride is not significantly removed by hemodialysis.

Therapeutic Uses of Amilorid

The Amiloride/Hydrochlorothiazide combination is considered relevant for use in conditions involving chronic cardiovascular and renal issues, where its therapeutic focus is centered on volume management and electrolyte preservation.

This medication is generally used across conditions presenting with significant symptomatic burden, including essential hypertension (high blood pressure) and fluid accumulation related to chronic heart failure or hepatic cirrhosis. It helps address symptoms related to physical discomfort like swelling (edema) by promoting diuresis, and it assists with maintaining a stable electrolyte balance during fluid reduction.

The combination is used when fluid management is appropriate, and the patient can benefit from support to conserve body potassium, which is relevant in clinical contexts. This supportive approach is applied in addressing symptoms associated with volume overload, which may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Swelling and Blood Pressure

The medication is commonly applied in scenarios where symptoms related to systemic imbalance are present, such as elevated blood pressure or excessive fluid accumulation. It may assist with lowering blood pressure and helps patients cope more steadily with the physical discomfort of edema in the extremities.

Regulatory References

  1. Amiloride Hydrochloride and Hydrochlorothiazide Tablets, USP Prescribing Information

Eligibility and Restrictions for Use

Amiloride Eligibility: Who Can and Cannot Use This Medicine

The eligibility profile for Amiloride is highly restricted, primarily due to the risk of hyperkalemia (high serum potassium levels).

Contraindicated Populations (Must Not Use)

Condition / Population Status
Hyperkalemia (Potassium > 5.5 mEq/L) Contraindicated
Other Potassium-Sparing Diuretics (e.g., spironolactone, triamterene) Contraindicated
Severe Renal Impairment (e.g., Anuria, Acute/Chronic Renal Insufficiency, Diabetic Nephropathy) Contraindicated
Hypersensitivity to Amiloride Contraindicated
Potassium Supplementation (medication, salt substitutes) Contraindicated

Populations Requiring Special Consideration

Population / Status Restriction
Pediatric Patients (under 18 years) Safety and efficacy not established; use is not recommended.
Diabetes Mellitus Requires careful, frequent, and continuing monitoring of electrolytes and renal function.
Older Adults (Geriatric) Use with caution; requires careful adjustment due to increased risk of electrolyte imbalance.
Pregnancy (FDA Category B) Use with caution; benefits must outweigh risks due to limited human data.
Lactation (Breastfeeding) Not recommended due to lack of data on infant safety.

Eligibility is strictly defined by regulatory documents, excluding patients with conditions that significantly increase the risk of severe potassium imbalance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the Amiloride and Hydrochlorothiazide combination, based strictly on government regulatory sources.


Interaction Scope

Category Official Regulatory Statement
Contraindicated Combinations Co-administration with other potassium-sparing agents (e.g., Spironolactone or Triamterene) or potassium supplements/salt substitutes is contraindicated due to a high risk of hyperkalemia.
Exposure-Altering Agents Diuretic agents reduce the renal clearance of Lithium, leading to a high risk of Lithium toxicity. Cholestyramine and Colestipol resins impair the absorption of Hydrochlorothiazide.
Pharmacodynamic Effects Co-administration with ACE Inhibitors or ARBs may increase the risk of hyperkalemia. Interactions with Corticosteroids or ACTH may result in intensified electrolyte depletion, particularly hypokalemia.
Administration Timing Cholestyramine or Colestipol must be taken 1 hour before or 4 hours after the diuretic combination.
Other Substances Alcohol, Barbiturates, or Narcotics may cause potentiation of orthostatic hypotension. NSAIDs may reduce the diuretic and antihypertensive effects.
Population Note The risk of hyperkalemia is accentuated in the presence of impaired renal function or diabetic nephropathy, and the risk of toxic reactions may be greater in the elderly.

Official Interaction Profile

The regulatory documents define this product’s interaction structure through a strict contraindication for any additional potassium source, underscoring the risk of elevated serum potassium. Other key interactions involve pharmacokinetic alterations like reduced renal clearance of Lithium, and reduced absorption of the diuretic component by certain resins. These factors establish the required constraints for safe co-administration, including mandatory timing rules and specific cautions for populations with renal impairment.

Mechanism of Action

The mechanism involves the dual inhibition of ion transporters in the kidney's final filtering segments, resulting in both increased fluid excretion and active potassium conservation.

Dual Blockade of Renal Salt Reabsorption

This domain describes the primary mechanism responsible for increased fluid excretion, where the two compounds act on different sections of the distal nephron. Hydrochlorothiazide inhibits the Thiazide-Sensitive Na^+- Cl^- Cotransporter (NCC), while Amiloride blocks the Epithelial Sodium Channel (ENaC) . This simultaneous action prevents the kidney from reclaiming sodium ( Na^+) and chloride ( Cl^-) at two key points, driving an osmotic cascade that increases the excretion of water and salt and subsequently reduces extracellular fluid volume.


Targeted Conservation of Potassium ( K^+)

This section focuses on the potassium-sparing mechanism of Amiloride. Its direct ENaC blockade eliminates the lumen-negative electrical potential normally created by sodium reabsorption, which is the gradient that drives the loss of K^+ ions into the urine. By removing this gradient, Amiloride promotes the retention of potassium, a physiological effect that counteracts the K^+ loss caused by the Hydrochlorothiazide mechanism.

Dosage and Administration Information

How to Use Amiloride/Hydrochlorothiazide

The Amiloride and Hydrochlorothiazide combination is a fixed-dose product intended for oral administration as a tablet. Usage is defined by administration requirements and dosing limits. The tablet must be swallowed whole and should always be taken with food to facilitate proper use.


Standardized Dosing and Frequency

For adults, the standard starting dose is typically one tablet (5 mg Amiloride / 50 mg Hydrochlorothiazide) administered once daily. Established guidelines define a dosage range, specifying that the dose may be adjusted during maintenance but must not exceed a maximum of two tablets (10 mg Amiloride / 100 mg Hydrochlorothiazide) per day. The daily dose may be taken all at once, or if two tablets are required, it may be administered in divided amounts. This fixed combination is generally used in maintenance therapy and is not indicated for the initial treatment of related conditions.


Administration Constraints

Usage constraints exist for this medication. The medication must not be administered concomitantly with other potassium-conserving agents or potassium supplements. Furthermore, the use of this drug is contraindicated in patients with established renal function impairments, including anuria, acute or chronic renal insufficiency, and evidence of diabetic nephropathy. Specific thresholds for use include elevated blood urea nitrogen (BUN) or serum creatinine levels.

Recent Clinical Evidence

Amilorid: Recent Clinical Evidence


Research Evidence for Managing High Blood Pressure (Essential Hypertension)

Studies involving Randomized Controlled Trials (RCTs) have been conducted to investigate the combination for high blood pressure. These trials are designed to randomly assign participants to the medicine or a comparison treatment, such as a placebo. Multicenter studies and published systematic reviews have also been used in this research area.

The studies were applied in research exploring how blood pressure changes over short periods, typically between 4 and 12 weeks. Researchers also monitored outcomes related to systemic imbalance, such as the levels of serum potassium, as well as tracking longer-term Cardiovascular Events (like stroke or heart attack) over several years. Study populations mainly included Adults with primary hypertension, with separate research specifically exploring the use in Older Adults.

Findings describe patterns observed in the studies, noting that research examined blood pressure stability and the frequency of major cardiovascular events. Research highlights changes measured during the study period, including variations in serum potassium levels. Certainty remains low regarding long-term metabolic effects in all subgroups, and the results apply only to the specific populations studied.


Research Evidence for Fluid Retention Associated with Heart Failure

Evidence for the use of this combination in managing fluid accumulation (edema) in patients with chronic heart failure has been evaluated in regulatory summaries and clinical practice guidance. Research exists within Regulatory Clinical Evaluation Summaries and data derived from trials examining the diuretic action and potassium-sparing properties of the components. The research was primarily applied in studies examining patient-reported experiences related to outcomes related to physical discomfort (swelling) and outcomes related to systemic imbalance (electrolyte levels).

Research has explored the diuretic action of the components, observing patterns related to Diuresis (fluid loss) and accompanying Weight Change. The critical outcome measured was Electrolyte Balance, specifically how the combination was observed alongside serum potassium stability. Evidence suggests its use is most relevant in trials assessing short-term or episodic symptom patterns where potassium conservation was an explicit research parameter.

Evidence is limited for dedicated, large-scale, long-term RCTs focusing on cardiovascular mortality specifically for this combination in heart failure populations. The evidence documents that study participants who presented with, or developed, impaired kidney function were monitored with particular attention during the study period. The body of evidence is more concentrated on the combined effect of the two components than on large, dedicated outcome studies for all heart failure subgroups.

Key Studies & References Amiloride Hydrochloride and Hydrochlorothiazide Tablets, USP Prescribing Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Amilorid (FAQ)


Q: What are the main therapeutic uses of Amilorid?

The Amiloride and Hydrochlorothiazide combination is indicated in official product information for the treatment of hypertension (high blood pressure) or congestive heart failure (CHF). This combination is typically used for patients who are at risk of developing low potassium (hypokalemia) when taking certain other diuretics. The combined action helps ensure stable potassium levels during treatment.

Q: Why do doctors prescribe Amilorid if it is considered a weak diuretic on its own?

Regulatory documents describe Amiloride itself as having weak diuretic and blood pressure-lowering activity when used alone. Its primary value, however, is its potassium-conserving property. When prescribed as a combination product, its role is to counteract the potassium loss caused by the other, more potent diuretic (like Hydrochlorothiazide).

Q: Is Amilorid a medication that is taken for the long term?

The drug combination is used in maintenance therapy for the long-term management of conditions like high blood pressure and fluid retention. Since these are often chronic conditions, treatment with antihypertensive agents is often continued indefinitely to help maintain control of the condition, but individual treatment plans are determined by a healthcare provider.

Q: What are the possible symptoms of having too much potassium in the blood while taking Amilorid?

Hyperkalemia, or high potassium, is the primary safety concern noted in the official labeling and can lead to serious cardiac effects. Warning signs of electrolyte imbalance that patients may be observed for include tiredness, weakness, restlessness, confusion, muscle pain or cramps, and tachycardia (a fast heart rate).

Q: Is it normal to feel dizzy or lightheaded when first starting Amilorid?

Official safety documents note that orthostatic hypotension (dizziness or lightheadedness upon standing) is an adverse effect that is more likely to occur at the start of therapy. This indicates it is a known possible effect during the initial phase of treatment.

Q: What happens if I miss a dose of Amilorid?

General patient information outlines the recommended process for managing a missed dose. If a dose is missed, individuals are generally advised to either take it immediately or skip it if the next scheduled dose is near. Taking extra medicine to make up for a missed dose is generally not advised. Consulting the patient information leaflet is important for specific guidance.

Q: Can a person stop taking Amilorid suddenly if they feel well?

Since this is a long-term treatment for conditions like hypertension, discontinuing the medication may lead to a loss of blood pressure control. Any change in the treatment plan should be decided upon by a healthcare provider.

Q: Are there any dietary restrictions I need to know about when taking Amilorid?

The main dietary restriction is the strict contraindication (reason not to use) of using potassium-containing salt substitutes or taking a potassium-rich diet. This warning is due to the high risk of hyperkalemia (high potassium), which is a serious safety concern.

Q: Which common foods are typically limited due to their high potassium content when on Amilorid?

Regulatory documents explicitly prohibit the use of a potassium-rich diet but do not list specific common foods in the official product label. This caution is in place due to the risk of excessive potassium buildup in the blood (hyperkalemia).

Q: What non-prescription supplements are known to interact with Amilorid?

The official labeling explicitly contraindicates the use of any type of potassium supplement, regardless of whether it is prescription or non-prescription. Other general supplements are not typically detailed in the major interaction sections.

Q: Is Amilorid known to affect cholesterol or triglyceride levels?

The medication contains Hydrochlorothiazide, which is noted in official documents as possibly raising serum levels of cholesterol and triglycerides. Regulatory documents mention that a healthcare provider may decide to monitor lipid levels.

Q: Are there any known issues with taking Amilorid if I have a history of gout?

Official labeling states that the Hydrochlorothiazide component may raise the serum uric acid level, which can cause or worsen hyperuricemia (high uric acid) and potentially precipitate a gout flare in people who are susceptible. Gout is also listed as an adverse event.

Q: Does Amilorid reduce the body's sodium levels?

Yes, the Hydrochlorothiazide component can cause a disturbance in fluid and electrolyte balance known as hyponatremia (low sodium). Patients are monitored for signs of this condition, which can occur during treatment.

Q: Can Amilorid cause muscle cramps or leg aches?

Yes, regulatory documents list muscle pains or cramps as possible warning signs of fluid and electrolyte imbalance. Muscular fatigue and leg ache are also noted as reported adverse events.

Q: Will taking Amilorid make me feel more tired or fatigued?

Official labeling includes both fatigue and tiredness as adverse reactions that have been reported by patients using this medication. These are common systemic effects associated with the drug.

Q: Does Amilorid cause sexual side effects, like decreased libido?

Yes, the adverse reactions reported in the official documents include several sexual side effects. These include decreased interest in sexual intercourse, inability to have or keep an erection (impotence), and a general loss in sexual ability, desire, drive, or performance.

Q: Can Amilorid cause a ringing in the ears (tinnitus)?

Yes, official safety information lists ringing, buzzing, or other unexplained noise in the ears (tinnitus) as a reported adverse event associated with the drug.

Q: Is Amilorid known to cause symptoms like increased thirst?

The official safety profile notes that increased thirst is a possible warning sign or symptom of fluid and electrolyte imbalance. Dry mouth is also documented as a common side effect of the medication.

Q: Can Amilorid cause digestive issues like diarrhea or gas?

Yes, reported adverse reactions cover a range of gastrointestinal disturbances. These include common issues such as nausea and constipation, as well as less common problems like diarrhea, abdominal pain, and flatulence (gas).

Q: Is it true that Amilorid can increase the risk of certain skin cancers?

Safety data associated with the Hydrochlorothiazide component shows a small increased risk of non-melanoma skin cancer (specifically basal cell and squamous cell carcinoma). This risk increases cumulatively over long periods of use.

Q: Can Amilorid cause vision changes or eye problems?

Official labeling for the Hydrochlorothiazide component notes that it can cause an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Other reported eye problems include disturbed color perception and blurred/loss of vision.

Q: How is the safety of Amilorid monitored in patients with diabetes?

Patients with diabetes mellitus require careful attention. Due to the high risk of hyperkalemia, official warnings emphasize the need for careful, frequent, and continuing monitoring of markers such as serum electrolytes, creatinine, and BUN levels.

Q: Does Amilorid pose a risk of kidney problems beyond hyperkalemia?

Impaired renal function is a major safety concern. Conditions such as anuria (absence of urine production), acute or chronic renal insufficiency, and evidence of diabetic nephropathy, are all listed as official contraindications (reasons not to use) for this product.

Q: What is the link between Amilorid and the body's acid-base balance?

Amiloride use may be associated with a change in the body's acid-base balance called metabolic acidosis. This is a safety consideration, as any shift in this balance can cause a rapid and unwanted increase in serum potassium levels.

Q: What is the general clinical profile of a patient who would be prescribed Amilorid?

The drug is prescribed for patients who have hypertension or congestive heart failure and need effective volume management while simultaneously maintaining normal serum potassium levels. The drug is contraindicated in patients who already have high potassium, renal impairment, or are taking potassium supplements.

Q: Is Amilorid ever prescribed for patients with cirrhosis of the liver?

Official warnings advise caution for patients with severe hepatic impairment, which includes cirrhosis, due to the potential for side effects. While the drug may be used in these populations, the labeling notes that liver disease can increase the chance of adverse effects and is often a reason for caution.

Q: What is the difference between Amilorid and Spironolactone, as both are potassium-sparing?

While both are potassium-sparing, they have different mechanisms: Amiloride directly blocks a channel in the kidney, while Spironolactone blocks the hormone aldosterone. Importantly, both drugs are officially contraindicated (must not be used) together due to the significantly increased risk of hyperkalemia.

Q: What is the relevance of blood pressure and heart rate when taking this drug?

The medication is indicated to treat hypertension (high blood pressure), but it can also cause orthostatic hypotension (low blood pressure when standing). Additionally, high potassium levels (hyperkalemia) pose a risk of life-threatening cardiac effects and arrhythmias (irregular heart rate), making heart function a key safety consideration.

Q: How long does it typically take to see the full therapeutic effect of Amilorid on blood pressure?

Clinical trials for the combination product have studied the effect on blood pressure over periods of between 4 and 12 weeks. This timeframe is generally considered necessary to assess the full therapeutic benefit of the medication.

Q: Is Amilorid used for conditions other than heart failure or high blood pressure?

The official indication is primarily for hypertension and congestive heart failure. Official labeling does not specify uses of the product outside of these formal indications.

How should Amilorid be stored and disposed of?

Storage and Disposal Requirements for Amiloride

Amiloride tablets must be stored at Controlled Room Temperature (20 C to 25 C), with permissible variations between 15 C and 30 C.

Storage conditions require that the medicine be kept in a tight, light-resistant container, away from moisture, excess heat, and must not be frozen. The container must remain tightly closed to maintain product integrity.

Protection and Discarding

It is an official requirement to Keep out of the reach and sight of children. Do not keep outdated medicine.

Disposal must follow local regulations. Expired or unused tablets should be taken to a drug take-back program. If unavailable, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a container before discarding in the household trash; do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amilorid found in:

A-Z Index: